10/27/2006 | BT | Market Commentary: Genzyme slides on deal buzz; Cadence, Achillion up; Aspreva falls; Vertex gains 18%; Critical off on PIPE
|
10/26/2006 | BT | Market Commentary: Achillion gains on debut; Cadence slips; DOV Pharma nosedives; Celgene better; Renovis falls 76%
|
10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
10/12/2006 | BT | Market Commentary: Genzyme gets AnorMED nod but hurt by 3Q; Nabi up 6% on asset sale; Trimeris off 13% on warning
|
10/11/2006 | BT | Market Commentary: Genentech slides, Xoma adds 8%; Genzyme eases; NitroMed sinks; Oscient gains; Northfield loses 3%
|
10/10/2006 | BT | Market Commentary: AnorMED gains 5% as Genzyme bests Millennium bid; DOV sinks 9% on hiring HSBC, up after close
|
10/6/2006 | BT | Market Commentary: Acorda up 10% as Elan, Biogen ease on Tysabri news; Panacos up on takeover; Memory up on PIPE
|
10/5/2006 | BT | Market Commentary: AnorMED up 7% as Genzyme boosts bid; GenVec gains 18%; Acorda rises; Light Sciences at bat
|
10/2/2006 | BT | Market Commentary: Gilead off, Myogen skyrockets; Accentia up, Biovest off; GTC up after close; Encysive off 3%
|
9/27/2006 | BT | Market Commentary: Nabi hires BofA, up after hours; Millennium off; BioSante dives 14.5%; BioCryst, Novavax gain
|
9/26/2006 | BT | AnorMED zooms after picking Millennium bid over Genzyme, but still seen firmly in play
|
9/26/2006 | BT | Market Commentary: AnorMED rockets on Millennium bid but still seen in play; Genzyme mum; Indevus slips on trial's end
|
9/25/2006 | BT | AnorMED says U.K. approval of Fosrenol triggers $3 million payment
|
9/20/2006 | BT | AnorMED gets shareholder backing to reject Genzyme offers
|
9/19/2006 | BT | Poniard expands picoplatin agreement with AnorMED
|
9/18/2006 | BT | AnorMED gets $3 million milestone payment for Fosrenol in Germany
|
9/7/2006 | BT | AnorMED to start trading on Nasdaq Global Market
|
9/5/2006 | BT | Market Commentary: Genta plunges 38%; Auxilium, Oscient slide; Warner-Chilcott IPO range set; AnorMED steady
|
8/31/2006 | BT | Market Commentary: Genta off 15.5%; EpiCept off on PIPE; AnorMED steady; Diomed gains 28%; ImmunoGen higher
|
8/30/2006 | BT | AnorMED rejects unsolicited Genzyme offer
|
8/30/2006 | BT | Market Commentary: AnorMED snubs Genzyme bid; PDL higher as Roche backs out; Vasogen zooms 42%; Adeza up
|
8/28/2006 | BT | AnorMED to transfer listing to Nasdaq, registers $100 million stock shelf
|
7/10/2006 | BT | AnorMED completes enrollment in first of two phase 3 trials of Mozobil in stem cell transplant
|
6/13/2006 | BT | AnorMED to focus on Mozobil development
|
5/24/2006 | BT | AnorMED president and chief executive Mike Abrams resigns
|
3/20/2006 | BT | AnorMED special shareholder meeting scheduled for April 21
|
3/17/2006 | BT | AnorMED's preclinical studies show AMD070 active in HIV patients
|
11/29/2005 | BT | AnorMED begins enrollment of patients in trial of anti-HIV drug AMD070
|
11/22/2005 | BT | New Issue: AnorMed prices C$25 million follow-on stock offering in bought deal
|
11/15/2005 | BT | AnorMED to present data showing Mozobil's potential in stem cell transplantation for cancer patients
|
11/3/2005 | BT | AnorMED stock to be listed on the Amex
|
11/1/2005 | BT | AnorMED gets OK to list shares on American Stock Exchange
|